Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community Hairline update - topical meds

      in Is this regrowth?  53 upvotes 8 months ago
      The conversation is about hair regrowth using topical finasteride, minoxidil, and keto spray, along with oral Saw Palmetto, Lustriva complex, collagen, and microneedling. Users discuss their experiences with these treatments, noting improvements in hair density and color, with some experiencing mild side effects.
      PP405 Identity Research

      community PP405 Identity Research

      in Research  292 upvotes 8 months ago
      PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

      community Fluridil (Eucapil) seems like a great option?

      in Treatment  4 upvotes 4 months ago
      The user stopped using finasteride due to side effects and is considering Fluridil (Eucapil) as an alternative for hair loss treatment. They are exploring other options like RU58841 and are interested in the experiences of others with Fluridil, noting its good safety profile despite the cost.

      community Guys, we finally have an alternative to finasteride

      in Research/Science  263 upvotes 11 months ago
      A combination of pyrilutamide, minoxidil, and alfatradiol is proposed as an effective alternative to finasteride for treating mild to moderate hair loss, claiming to stabilize hair loss and improve thickness without finasteride's side effects. Some users are skeptical about the effectiveness and approval of these treatments, while others are interested in trying them due to finasteride's side effects.

      community Binding affinity of pyrilutamide!

      in Update  168 upvotes 3 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.